Reduction of mtDNA heteroplasmy in mitochondrial replacement therapy by inducing forced mitophagy

Mitochondrial replacement therapy (MRT) has been used to prevent maternal transmission of disease-causing mutations in mitochondrial DNA (mtDNA). However, because MRT requires nuclear transfer, it carries the risk of mtDNA carryover and hence of the reversion of mtDNA to pathogenic levels owing to selective replication and genetic drift. Here we show in HeLa cells, mouse embryos and human embryos that mtDNA heteroplasmy can be reduced by pre-labelling the mitochondrial outer membrane of a donor zygote via microinjection with an mRNA coding for a transmembrane peptide fused to an autophagy receptor, to induce the degradation of the labelled mitochondria via forced mitophagy. Forced mitophagy reduced mtDNA carryover in newly reconstructed embryos after MRT, and had negligible effects on the growth curve, reproduction, exercise capacity and other behavioural characteristics of the offspring mice. The induction of forced mitophagy to degrade undesired donor mtDNA may increase the clinical feasibility of MRT and could be extended to other nuclear transfer techniques. The carryover of mitochondrial DNA in mitochondrial replacement therapy can be reduced via forced mitophagy by pre-labelling the mitochondrial outer membrane of a donor zygote with an autophagy receptor, as shown in mouse and human embryos.

Automated summary

Forced mitophagy can reduce mtDNA carryover in mitochondrial replacement therapy by pre-labelling the mitochondrial outer membrane of a donor zygote with an autophagy receptor, as shown in mouse and human embryos.